Oxaliplatin: A Novel Platinum Analog With Activity in Colorectal Cancer

Deborah T. Berg

ONF 2003, 30(6), 957-966. DOI: 10.1188/03.ONF.957-966

Purpose/Objectives: To review selected recent data pertaining to the use of oxaliplatin in colorectal cancer and its implications for oncology nursing.

Data Sources: Published articles, abstracts, and conference proceedings.

Data Synthesis: Colorectal cancer accounts for about 15% of all new cancers. The search for more effective chemotherapy regimens is ongoing. Oxaliplatin, a member of the diaminocyclohexane family of platinum compounds, demonstrates cytotoxic efficacy and a well-tolerated safety profile.

Conclusions: Oxaliplatin is effective in chemotherapy-naive patients with advanced colorectal cancer, as well as in those refractory to previous treatment with 5-fluorouracil (5-FU); the drug also is effective in combination with 5-FU and leucovorin for the treatment of advanced colorectal cancer.

Implications for Nursing: Nurses must be highly knowledgeable about oxaliplatin regimens and schedules, the associated side effects, and recommended strategies for symptom management. This article can help nurses to understand and communicate the benefits and risks associated with oxaliplatin-based therapies to colleagues and patients.

Jump to a section

    References

    Advanced Colorectal Cancer Meta-Analysis Project. (1992). Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Journal of Clinical Oncology, 10, 896-903.

    Almadrones, L.A., & Arcot, R. (1999). Patient guide to peripheral neuropathy. Oncology Nursing Forum, 26, 1359-1360.

    Baur, M., Kienzer, H.R., Rath, T., & Dittrich, C. (2000). Extravasation of oxaliplatin (Eloxatin)—Clinical course. Onkologie, 23, 468-471.

    Becouarn, Y., & Rougier, P. (1998). Clinical efficacy of oxaliplatin mono-therapy: Phase II trials in advanced colorectal cancer. Seminars in Oncology, 25, 23-31.

    Berg, D.T. (2001). Systemic chemotherapy for colorectal cancer. In D.T. Berg (Ed.), Contemporary issues in colorectal cancer: A nursing perspective (pp. 157-190). Boston: Jones and Bartlett.

    Berg, D.T. (2003). Pocket guide to colorectal cancer. Boston: Jones and Bartlett.

    Bismuth, H., & Adam, R. (1998). Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Seminars in Oncology, 25(2 Suppl. 5), 40-46.

    Bleiberg, H. (1996). Role of chemotherapy for advanced colorectal cancer: New opportunities. Seminars in Oncology, 23, 42-50.

    Brienza, S., Vignoud, J., Itzhaki, M., & Krikorian, A. (1995). Oxaliplatin (L-OHP): Global safety in 682 patients [Abstract]. Proceedings of the American Society of Clinical Oncology, 14, 209.

    Colvin, O.M. (1997). Alkylating agents and platinum antitumor compounds. In J. F. Holland, R.C. Bast, Jr., D.L. Morton, E. Frei, III, D.W. Kufe, & R.R. Weichselbaum (Eds.), Cancer medicine (4th ed., pp. 949-975). Baltimore: Williams and Wilkins.

    Cunningham, D., Pyrhonen, S., James, R.D., Punt, C.J., Hickish, T.F., Heikkila, R., et al. (1998). Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 352, 1413-1418.

    Cvitkovic, E., & Bekradda, M. (1999). Oxaliplatin: A new therapeutic option in colorectal cancer. Seminars in Oncology, 26, 647-662.

    de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology, 18, 2938-2947.

    Desrame, J., Broustet, H., Darodes de Tailly, P., Girard, D., & Saissy, J.M. (1999). Oxaliplatin-induced haemolytic anaemia. Lancet, 354, 1179-1180.

    Diaz-Rubio, E., Sastre, J., Zaniboni, A., Labianca, R., Cortes-Funes, H., de Braud, F., et al. (1998). Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study. Annals of Oncology, 9, 105-108.

    Dold, F., Hoey, D., Carberry, M., Musket, A., Friedberg, V., & Mitchell, E. (2002). Hypersensitivity in patients with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin [Abstract]. Proceedings of the American Society of Clinical Oncology, 21, 370a.

    Douillard, J.Y., Cunningham, D., Roth, A.D., Navarro, M., James, R.D., Karasek, P., et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet, 355, 1041-1047.

    Drummond, J.T., Anthoney, A., Brown, R., & Modrich, P. (1996). Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. Journal of Biological Chemistry, 271, 19645-19648.

    Extra, J.M., Espie, M, Calvo, F., Ferme, C, Mignot, L., & Marty, M. (1990). Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 25, 299-303.

    Extra, J.M., Marty, M., Brienza, S., & Misset, J.L. (1998). Pharmacokinetics and safety profile of oxaliplatin. Seminars in Oncology, 25(2 Suppl. 5), 13-22.

    Findlay, M., Van Cutsem, E., Kocha, W., Allman, D., Laffranchi, B., Griffin, T., et al. (1997). A randomized phase II study of Xeloda (capecitabine) in patients with advanced colorectal cancer [Abstract]. Proceedings of the American Society of Clinical Oncology, 16, 798.

    Finley, R.S. (1991). The pharmacology of cancer chemotherapy. In R.S. Finley (Ed.), Concepts in oncology therapeutics (pp. 73-94). Bethesda, MD: American Society of Hospital Pharmacists.

    Gamelin, E., Gamelin, L., Delva, R., Guerin-Meyer, V., Morel, A., Boisdron-Celle, M., et al. (2002). Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/Mg+ chloride infusions: A retrospective study [Abstract]. Proceedings of the American Society of Clinical Oncology, 21, 624.

    Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., et al. (2000). Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology, 18, 136-147.

    Gilles-Amar, V., Garcia, M.L., Sebille, A., Maindrault-Goebel, F., Louvet, C., Beerblock, K., et al. (1999). Evolution of severe sensory neuropathy with oxaliplatin combined to the bimonthly 48h leucovorin (LV) and 5-fluorou-racil (5FU) regimens (FOLFOX) in metastatic colorectal cancer [Abstract]. Proceedings of the American Society of Clinical Oncology, 18, 944a.

    Goldberg, R.M., Morton, R.F., Sargent, D.J., Fuchs, C.S., Ramanathan, R.K., Williamson, S.K., et al. (2002). N9741: Oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Inter-group study [Abstract]. Proceedings of the American Society of Clinical Oncology, 21, 511.

    Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M., & Gamelin, E. (2001). A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. Neurophysiology, 85, 2293-2297.

    Grothey, A., Deschler, B., Kroening, H., Ridwelski, K., Reichardt, P., Kretzschmar, A., et al. (2002). Phase III study of bolus 5-fluorouracil (5-FU) infusion/folinic acid (FA) (Mayo) vs weekly high dose 24h 5-FU in-fusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACR) [Abstract]. Proceedings of the American Society of Clinical Oncology, 21, 512.

    Harper, P. (1997). Advanced colorectal cancer (ACC): Results from the latest raltitrexed Tomudex (raltitrexed) comparative study. Proceedings of the American Society of Clinical Oncology, 16, 228a.

    Hills, C.A., Kelland, L.R., Abel, G., Siracky, J., Wilson, A.P., & Harrap, K.R. (1989). Biological properties of ten human ovarian carcinoma cell lines: Calibration in vitro against four platinum complexes. British Journal of Cancer, 59, 527-534.

    Hoff, P.M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kupermine, M., et al. (2001). Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. Journal of Clinical Oncology, 19, 2282-2292.

    Iirillo, A., Morabito, A., Mariella, S., Palazzolo, G., Errante, D., Manente, P., et al. (2000). Folfox2 regimen in treatment with metastatic colorectal cancer (MCRC) [Abstract]. Proceedings of the American Society of Clinical Oncology, 19, 1099.

    Jansman, F.G., Sleijfer, D.T., de Graaf, J.C., Coenen, J.L., & Brouwers, J.R. (2001). Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Safety, 24, 353-367.

    Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M.J. (2003). Cancer statistics, 2003. CA A Cancer Journal for Clinicians, 53, 5-26.

    Kennedy, J.G., Donahue, J.P., Hoang, B., & Boland, P.J. (2003). Vesicant characteristics of oxaliplatin following antecubital extravasation. Clinical Oncology, 15, 237-239.

    Leichman, C., Pendyala, L., Leichman, L., Proefrock, A., Regal, L., Habboubi, N., et al. (2000). A phase I drug interaction study of oxaliplatin (OXA) and 5-fluorouracil (5-FU) administered by bolus injection (BI) or continuous infusion (CI) [Abstract]. Proceedings of the American Society of Clinical Oncology, 19, 1270.

    Levi, F., Metzger, G., Massari, C., & Milano, G. (2000). Oxaliplatin: Pharmacokinetics and chronopharmacological aspects. Clinical Pharmacokinetics, 38, 1-21.

    Levi, F., Missel, J.L., Brienza, S., Adam, R., Metzger, G., Itzakhi, M., et al. (1992). A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High anlilumor effectiveness against metastatic colorectal cancer. Cancer, 69, 893-900.

    Levi, F., Perpoint, B., Garufi, C., Focan, C., Chollet, P., Depres-Brummer, P., et al. (1993). Oxaliplatin activity against metastatic colorectal cancer: A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. European Journal of Cancer, 29A, 1280-1284.

    Levi, F., Zidani, R., & Misset, J. (1997). Randomized, multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastalic colorectal cancer. International Organization for Cancer Chemotherapy. Lancet, 350, 681-686.

    Levi, F.A., Zidani, R., Vannetzel, J.M., Perpoint, B., Focan, C., Faggiuolo, R., et al. (1994). Chronomodulated versus fixed-infusion rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. Journal of the National Cancer Institute, 86, 1608-1617.

    Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J.J., Brienza, S., et al. (1996). Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Annals of Oncology, 7, 95-98.

    Mariani, G., Garrone, O., Granetto, C., Numico, G., LaCiura, P., Grecchi, G., et al. (2000). Oxaliplatin induced neuropathy: Could gabapentin be the answer? [Abstract]. Proceedings of the American Society of Clinical Oncology, 19, 2397.

    Milano, G., & Etienne, M.C. (1996). Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: Theory and limits. Therapeutic Drug Monitoring, 18, 335-340.

    Mitchell, E.P. (2000). Oxaliplatin with 5-FU or as a single agent in advanced/ metastatic colorectal cancer. Oncology (Huntington), 14(12 Suppl. 11), 30-32.

    National Cancer Institute. (2002a). New drug regimen shows clear benefit for treating advanced colorectal cancer. Retrieved May 22, 2002, from http://newscenter.cancer.gov/pressreleases/ASCON9741.html

    National Cancer Institute. (2002b). PDQ clinical trials database. Retrieved May 22, 2002, from http://www.cancer.gov/search/clinical_trials

    Pazdur, R. (1998). New agents for colorectal cancers: Oral fluorinated pyrimidines and oxaliplatin. In M. Perry (Ed.), ASCO education book (pp. 300-310). Alexandria, VA: American Society of Clinical Oncology.

    Pazdur, R., & Vincent, M. (1997). Raltilrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): Results of a randomized, multicenter, North American trial [Abstract]. Proceedings of the American Society of Clinical Oncology, 16, 228a.

    Perez, R.P., O'Dwyer, P.J., Handel, L.M., Ozols, R.F., & Hamilton, T.C. (1991). Comparative cytotoxicily of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines. International Journal of Cancer, 48, 265-269.

    Raymond, E., Chaney, S.G., Taamma, A., & Cvitkovic, E. (1998). Oxaliplatin: A review of preclinical and clinical studies. Annals of Oncology, 9, 1053-1071.

    Raymond, E., Faivre, S., Woynarowski, J.M., & Chaney, S.G. (1998). Oxaliplatin: Mechanism of action and antineoplaslic activity. Seminars in Oncology, 25(2 Suppl. 5), 4-12.

    Reed, E. (1993). Platinum analogs. In V.T. DeVita, Jr., S. Hellman, & S.A. Rosenberg (Eds.), Cancer: Principles and practice of oncology (4th ed., pp. 390-400). Philadelphia: Lippincott.

    Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., et al. (1996). Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochemical Pharmacology, 52, 1855-1865.

    Roche Laboratories. (2001). Xeloda [Package insert]. Nutley, NJ: Author.

    Rothenberg, M.L., Eckardt, J.R., Kuhn, J.G., Burris, H.A., III, Nelson, J., Hilsenbeck, S.G., et al. (1996). Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Journal of Clinical Oncology, 14, 1128-1135

    Rothenberg, M.L., Oza, A.M., Burger, B., Berlin, J., Marshall, J.L., Ramanathan, R.K., et al. (2003). Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Retrieved July 20, 2003, from http://www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00101770-00_29-00A,00.asp

    Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., et al. (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet, 352, 1407-1412.

    Rudolph, S., Ridwelski, K., Kuhn, R., & Lippert, H. (2000). Randomized trial with or without amifostin to reduce neurotoxicity side effects under chemotherapy with oxaliplatin, FA/5-FU. Annals of Oncology, 11(Suppl. 4), 154.

    Sadahiro, S., Mukai, M., Tokunaga, N., Tajima, T., & Mitomi, T. (1998). Preliminary study on the new optimal dosage schedule for oral UFT. International Journal of Clinical Oncology, 3, 7-12.

    Saltz, L., Meropol, N.J., Loehrer, P.J., Waksal, H., Needle, M.N., Mayer, R.J., et al. (2002). Single agent IMC-C225 (Eribitux) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR) [Abstract]. Proceedings of the American Society of Clinical Oncology, 21, 127a.

    Saltz, L.B., Cox, J.V., Blanke, C., Rosen, L.S., Fehrenbacher, L., Moore, M.J., et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 343, 905-914.

    Sanofi-Synthelabo, Inc. (1998). [Oxaliplatin.] Data on file.

    Sanofi-Synthelabo, Inc. (2002). Eloxatin [Package insert]. New York: Author.

    Scheithauer, W., Rosen, H., Korneck, G.V., Sebesta, C., & Depisch, D. (1993). Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ, 306, 752-755.

    Schmoll, H.J. (1996). Development of treatment for advanced colorectal cancer: Infusional 5-FU and the role of new agents. European Journal of Cancer, 32A(Suppl. 5), S18-S22.

    Schmoll, H.J., & Cassidy, J. (2001). Integrating oxaliplatin into the management of colorectal cancer. Oncologist, 6(Suppl. 4), 24-28.

    Silvestro, L., Anal, H., Sommer, F., Trincal, G., & Taplero, H. (1990). Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum; L'OHP) with CDDP on various cells: Correlation with intracellular accumulation [Abstract]. Anticancer Research, 10, 1376

    Vaisman, A., Varchenko, M., & Chaney, S.G. (1997). Correlation between mismatch repair defects and increased replicative bypass in cisplatin resistant cell lines [Abstract]. Proceedings of the American Association of Cancer Research, 38, A2091.

    Van Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., et al. (2001). Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. Journal of Clinical Oncology, 19, 4097-4106.

    Von Hoff, D.D., Rothenberg, M.L., Pilot, H.C., Elfring, G.L., Mohrland, J.S., Schaaf, L.J., et al. (1997). Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): Overall results of FDA-reviewed pivotal U.S. clinical trials [Abstract]. Proceedings of the American Society of Clinical Oncology, 16, 228a.

    Wilkes, G.M. (2002). New therapeutic options in colon cancer: Focus on oxaliplatin. Clinical Journal of Oncology Nursing, 6, 131-137.

    Wiseman, L.R., Adkins, J.C., Plosker, G.L., & Goa, K.L. (1999). Oxaliplatin: A review of its use in the management of metastatic colorectal cancer. Drugs and Aging, 14, 459-475.